Kodiak Sciences Inc.

NASDAQ:KOD

Biotechnology

Healthcare
$97.81 -0.08%

-$0.03 today

Market cap
$6.40B
Beta
2.21
P/E (TTM)
-9.6
EPS (TTM)
-$3.73
52W Low $3.43High $47.84

Volume 0.74M

Average 1.10M

KOD Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Kodiak Sciences Inc.NASDAQ: KOD

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares growth accelerates

Q3 FY2026 weighted avg shares of 62.96M shares rose 19.1% year over year, ahead of the +14.0% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at +0.6% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +19.1% holds above the trailing-twelve-month pace of +14.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
62.96M+0.5% QoQ
Last fiscal yearDec 2025
53.21M+1.2% YoY
LTMSep 2026
60.16M+14.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+19.1%——
1 year+1.2%——
3-year CAGR+0.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
53.21M USD
Year-over-year change
+1.2%
4-year CAGR
+0.7%

Weighted Avg Shares vs competitors

How KOD compares with its peers on the latest reported figures

  • KOD's LTM Sep 2026 weighted avg shares of 60.16M shares is the 6th highest of the 10 companies compared; the peer median is 77.28M shares.
  • Its year-over-year change of +14.0% is the 6th highest of 10, against a peer median of +19.1%.
  • Over three fiscal years its annual growth of +0.6% compares with a peer median of +18.9%.
KOD Competitors Peer median
Weighted Avg Shares for KOD and competitors
Company Period LTM YoY 3-year CAGR
BLCOBausch + Lomb CorporationLTM Jun 2026355.23M +0.8%+0.4%
OCGNOcugen, Inc.LTM Mar 2026307.2M +9.9%+11.8%
OCULOcular Therapeutix, Inc.LTM Mar 2026200.88M +19.9%+34.5%
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026103.48M -3.2%-0.8%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 202677.28M +27.7%+25.2%
KODKodiak Sciences Inc.LTM Sep 202660.16M +14.0%+0.6%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 202659.51M +7.9%+21.4%
OCSOculis Holding AGLTM Mar 202654.96M +27.5%+16.9%
OTLKOutlook Therapeutics, Inc.LTM Mar 202653.45M +120.6%+48.6%
BLTEBelite Bio, IncLTM Sep 202638.5M +19.1%+18.9%
Peer median (excluding KOD) 77.28M+19.1%+18.9%

Competitors are the stored peer set for KOD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue8.71M11M25.95M26.71M0
Gross Profit(8.71M)(11M)(25.95M)(26.71M)0
Gross Margin—————
Research & Development217.34M267.59M206.3M126.1M182.37M
Selling, General & Admin41M62.79M71.02M34.05M52.02M
Operating Expenses258.34M330.38M251.37M160.14M234.39M
Depreciation & Amortization8.71M11M25.95M26.71M26.32M
EBITDA(258.26M)(322.8M)(234.53M)(149.5M)(203.65M)
EBITDA Margin—————
Operating Income(267.05M)(341.38M)(277.32M)(186.85M)(234.39M)
Operating Margin—————
Interest Income298K7.07M16.73M11.15M4.52M
Interest Expense22K18K13K00
Other Income / Expenses61K7.56M16.83M10.64M4.42M
Income Before Tax(266.99M)(333.82M)(260.49M)(176.21M)(229.97M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(266.99M)(333.82M)(260.49M)(176.21M)(229.97M)
Net Margin—————
EPS (Basic)(5.16)(6.39)(4.97)(3.35)(4.32)
EPS (Diluted)(5.16)(6.39)(4.97)(3.35)(4.32)
Weighted Avg Shares51.79M52.25M52.41M52.58M53.21M
Weighted Avg Shares (Diluted)51.79M52.25M52.41M52.58M53.21M

Kodiak Sciences Inc.

NASDAQ:KOD

Intrinsic Alpha fair value

Locked

Current Price

$97.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.